Drug Trial Radar · NCT05048056
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
79
Actual
Start
Sep 30, 2021
Primary completion
May 17, 2023
Study completion May 17, 2023
Sponsor
- Lead sponsor
- Akesobio Australia Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
PlaceboDrug
Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1
AK120Drug
AK120 Regimen 1- subcutaneous injection every 2 weeks.
AK120Drug
AK120 Regimen 2- subcutaneous injection every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving an Eczema Area and Severity Index (EASI) 75 responseTime frame: At week 16
Locations
24 sites in 3 countries. Site status is shown where the registry gives one.
AkesoBio Investigative Site 2003
Little Rock, Arkansas
AkesoBio Investigative Site 2010
Canoga Park, California
AkesoBio Investigative Site 2021
San Diego, California
AkesoBio Investigative Site 2023
San Diego, California
AkesoBio Investigative Site 2017
San Francisco, California
AkesoBio Investigative Site 2020
Sherman Oaks, California
AkesoBio Investigative Site 2009
Hialeah, Florida
AkesoBio Investigative Site 2001
Hollywood, Florida
AkesoBio Investigative Site 2011
Miami, Florida
AkesoBio Investigative Site 2002
Weston, Florida
AkesoBio Investigative Site 2022
Ridgeland, Mississippi
AkesoBio Investigative Site 2015
Las Vegas, Nevada
AkesoBio Investigative Site 2013
Spartanburg, South Carolina
AkesoBio Investigative Site 2005
Rapid City, South Dakota
AkesoBio Investigative Site 2004
Houston, Texas
AkesoBio Investigative Site 2018
Houston, Texas
AkesoBio Investigative Site 3003
Sydney, New South Wales, Australia
AkesoBio Investigative Site 3002
Woolloongabba, Queensland, Australia
AkesoBio Investigative Site 3001
Camberwell, Victoria, Australia
AkesoBio Investigative Site 4003
Auckland, New Zealand
AkesoBio Investigative Site 4001
Auckland, New Zealand
AkesoBio Investigative Site 4005
Christchurch, New Zealand
AkesoBio Investigative Site 4004
Hamilton, New Zealand
AkesoBio Investigative Site 4004
Wellington, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.